Statistics from Altmetric.com
We appreciate the interest that Reginster and colleagues1 showed in our publication on subgroup effects of oral glucosamine for osteoarthritis (OA).2 We are pleased that the eLetter authors do not put forward any critique of our publication that requires our justification or clarification.
As highlighted by the authors,1 the effectiveness of oral glucosamine products for knee and hip OA symptoms has been questioned. Nevertheless, due to the heterogeneous nature of the disease, whether certain subgroups of patients with OA could benefit from glucosamine has not been excluded. Since available randomised controlled trials are usually not powered to show subgroup effects, …
Handling editor Tore K Kvien
Competing interests None declared.
Provenance and peer review Commissioned; internally peer reviewed.
Correction notice This article has been corrected since it published Online First. The third author’s name has been corrected to Marienke van Middelkoop.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.